BHVN

Biohaven develops biopharmaceutical treatments across immunology, neuroscience, and oncology using proprietary drug platforms, with a current focus on three late-stage clinical programs: Kv7 ion channel modulators for epilepsy, extracellular protein degraders (MoDE and TRAP) for immunological diseases, and myostatin-activin pathway inhibitors for neuromuscular and metabolic diseases including obesity. The company spun off as an independent public company in October 2022 and is advancing multiple candidates in Phase 1 trials with plans to initiate pivotal studies in 2026.

Pipeline

Catalyst Calendar